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Chemical carcinogen-induced tumors evoke resistance to rechallenge which is
unique to the immunizing tumor and does not extend to syngeneic tumor cells in
most systems which have been investigated (1-3). By contrast when in vitro
techniques such as colony inhibition (4, 5) or microcytotoxicity (6, 7) are
employed, similar families of syngeneic tumors reveal common or shared
antigens as targets for tumor-immune lymphoid cells. As an approach to
resolving this apparent paradox, we have used solubilized preparations from such
tumors to induce tumor-specific resistance in vivo, and to assess in vitro
reflections of tumor immunity at the cellular level.
The in vitro assay is based upon measuring proliferation induced in lymphoid
cells from tumor-bearing or tumor-immune mice by KCI-solubilized membranes
derived from families of syngeneic methylcholanthrene (MCA)'-induced fi-
brosarcomas. Kinetic parameters of the assay are explored in detail, and
evidence is developed that the antigen-lymphoid cell interaction in vitro has
immunologic specificity. The assay is used to explore the evolution of bearing
transplanted tumors and the transplantation-resistant states which follow
surgical tumor excision or immunization with the soluble tumor antigens. Both
in vitro and in vivo data suggest the probable existence of multiple antigenic
components on such tumor cells and that some, but not all, of these components
are shared with syngeneic tumors .
Materials and Methods
Mice. Age-matched, 7- to 8-wk old female C57BL/6, C57BL/10, C57BL/IO-BR and C57BL/
10-D2, obtained directly from Jackson Laboratories, Bar Harbor, Maine, were used in all
experiments.
Tumors.
￿
Fibrosarcomas were induced in each strain by injecting 0.5 mg MCA in 0.1 ml olive oil
intramuscularly (i.m .) in four sites. The tumors which arose 6-12 wk later were frozen after a single
* This work was supported in part by U. S. Public Health Service grants AI-00401, CA-15334, and
HD-00384. This is publication no. 96 from the Tumor Biology Unit, Department of Pathology,
University of Florida College of Medicine, Gainesville, Fla. 32610.
'Abbreviations used in this paper: FCA, Freund's complete adjuvant; LN, lymph node; MCA,
methylcholanthrene; PBL, peripheral blood leukocytes; and [3H]TdR, ['H]thymidine.
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syngeneic passage, then carried in syngeneic female mice an average of four passages while being used
to provide the experimental tumor inoculum. The tumors used in the experiments presented in this
paper are in the C57BL/6 (C57-Ml, C57-M2, C57-M3, C57-M4, C,57-M1, and C657-M2) or
C57BL/10- BR (1310 .1311-Ml, B10-BR-M2, and B10-BR-M3) lines. Tumor cell suspensions were
prepared as previously described (8) andtransplanted by i.m. inoculation into the distal thigh of8-wk
old mice.
Because in vitro and in vivo evidence for immunity to multiple or shared antigens was discovered
in the course of these experiments, a convention for the tumor-host relationship terminology hasbeen
adopted for clarity. "Homologous" tumor refers to that specific tumor or soluble antigen derived from
the tumor which the animal is bearing, or the tumor to which it has been immunized. "Syngeneic
tumor," or the soluble products thereof, refers to all other MCA-induced tumors raised in that same
strain or subline of mice.
Soluble TumorAntigens.
￿
Soluble tumor antigens were prepared by modification of the method of
Reisfeld et al. (9). All operations were conducted under strictly aseptic conditions and involved
sterile pyrogen-free solutions. Carefully dissected fresh tumor tissue was suspended in sterile
pyrogen-free phosphate-buffered saline containing 3M KCl at pH 7.4 (2 ml solvent/1 goriginal tumor
tissue weight) and briefly disrupted at 4° C by homogenization in a sterilized Sorvall blender (Ivan
Sorvall, Inc., Newtown, Conn .). This suspension was stirred at 4°C for 16 h, then centrifuged at
225,000 g for an additional 60 min. The resulting supernatant preparations (hereafter called tumor
antigen) were exhaustively dialysed against phosphate-buffered saline, diluted to a uniform level of
absorbance at 280nm, passed through a 0.2 gm millipore filter, and stored no longer than 3-4 wk at
4°C until used. The preparations are referred to in the text by the strain and anumber designation
followed by the bracketed suffix [sJ; for example, B10-M4[s] is soluble antigen prepared from the M4
tumor raised in C57BL/10 mice. The solubilized tumor preparations were tested and found to be
negative for pyrogenicity in rabbits by standard methods.
Cell Preparations.
￿
Spleen or lymph node (LN) cells were removed after exsanguination via the
abdominal aorta, minced with scissors, and passed through sterile 60 mesh stainless steel screens
using RPMI-1640 as the suspending medium. Cells were then freed from clumps by drawing the
suspension through 25-gauge needles, and total cell counts were determined for each cell mass
assayed.
Peripheral blood was collected from the retro-orbital plexus using heparinized tubes. A total and
differential cell count wasmade, the blood wascentrifuged at 2,000 rpm for 20 min, andthe buffy coat
and serum were collected in cold RPMI-1640. The pooled peripheral blood leukocyte (PBL)
suspension was washed twice with cold PRMI-1640. The results were related to the absolute
lymphocyte count.
Assay for Mitogen and TumorAntigen Stimulation.
￿
The culture medium employed throughout
consisted of RPMI-1640 to which 100 Wg streptomycin/ml had been added together with 56°C
heat-activated human serum. The culture method has been reported in detail in previous papers (9,
10). The antigens or mitogens were added to polypropylene culture tubes (12 x 75 mm, BioQuest
Div., Becton, Dickinson & Co., Cockeysville, Md.) containing 1 x 106 cells, then cultured for 72 h in
5% CO, in air. Tumor antigens were added in the amounts indicated in each instance to cultures
containing 0.5, 1 x 106, or 2 x 106 cells in 0.5 ml culture medium and incubated for 72 h.
Dose-response titrations were performed in all assays; that dose giving maximalincorporation values
is reported in some of the experiments to be described. ['H]thymidine (['H]TdR) incorporation was
assayed by the method previously reported (8, 10) . The data obtained are presented as mean values t
standard error (SE) for four replicate cultures at each dose level.
AssayofImmunogenicity of Growing Tumors or Solubilized TumorAntigens.
￿
The immunogenic-
ity of each tumor was assayed initially by the classical transplantation technique in syngeneic
recipients (11) . Groups of five mice were injected with 1 x 105 viable tumor cells in the hind limb. 7
days later this limb was surgically excised ; the mice were then challenged 7 days later with 10-fold
incremental numbers of tumor cells (1 x 102-1 x 106) s.c. in the other hind limb. Tumor growth was
assessed by weekly measurement of tumor sizes for 5 wk. Control animals didnot receive a priming
injection of tumor, but their hind limb was amputated at the same time as tumor bearers, and both
were challenged with tumor on the same schedule.
In order to assay for immunogenicity of tumor antigen preparations, 0.1 mg KCl-solubilized tumor
material was incorporated into Freund's complete adjuvant (FCA) and injected i.m. into groups ofJAMES T. FORBES, YOSHINOBU NAKAO, AND RICHARD T. SMITH
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five mice (12, 13). 4 wk later the injection was repeated s.c., and 1 wk after that groups of such
animals, together with controls which had received only FCA, were challenged with incremental
numbers of viable tumor cells. Tumor growth was measured at weekly intervals thereafter.
Results
Kinetics of Stimulation of Lymphoreticular Cells by Homologous Solubilized
Tumor Preparations. To determine the optimal conditions for the in vitro
stimulation of proliferation induced by 3 M KCl-solubilized MCA tumors,
experiments were performed involving multiple variations in culture conditions,
dose-response relationships, and time-course kinetics. The data presented in
Table I and Figs. 1-3 are representative of kinetic data obtained in over 100
similar experiments done in various contexts. The correlation between the
TABLE I
Time Course of ['H]TdR Incorporation Stimulation by C57-M4[s] in
Cultures of Spleen Cells from C57-M4-bearing C57BL/6Mice*
* Cultures of 2 x 106 normal C57BL/6 or C57BL/6M4-bearing spleen cells
(21 days postinoculaton) were established, and graded amounts of
C57BL/6 M4[s] were added; the cultures were terminated and ['H]TdR
incorporation (added 24 h earlier) was assayed. Data shown represent
mean peak incorporation values t SE.
kinetics of stimulation and the evolution of tumor immunity at the cellular level
will be considered in a later section.
The typical time-coursekinetics of solubilized antigen-induced proliferation in
spleen cells taken from tumor-bearing mice are shown in Table I. Discrimination
between spontaneous proliferation in unstimulated (control) cells from tumor-
bearing animals and peak proliferation induced in those cultured with C57BL/
6[s] was maximal at 72 h of culture. This culture interval was employed for all
subsequent assays.
Dose-response titrations of cells taken from tumor-bearing hosts gave data
which varied according to the population of cells assayed, the interval after
tumor inoculation or amputation, and other factors. The range of proliferation
behavior observed in PBL from both normal and tumor-bearing mice, in response
to solubilized homologous tumor, is illustrated in Fig. 1. The data are corrected to
the absolute number of circulating lymphocytes since granulocytosis occurs
progressively over the course of bearing these tumors. PBL from normal mice
show little or no detectable [ 3H]TdR incorporation when cultured in the pres-
ence of solubilized tumor preparations. Two general patterns of dose-response
kinetics were observed. The most prevalent pattern (Fig. 1 a) resembled closely
Duration ofcultures
[3H]TdR incorporation
Control C57-M4 [s] added
h mean cpm t SE/106 cells
24 32,109 t 537 37,249 t 559
48 2,888 t 255 4,636 t 293
72 2,533 t 89 6,370 t 149
96 218 t 14 215 t 71184
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Dose-response relationship of PBL from normal and tumor-bearing mice induced by
added soluble homologous tumor antigen. The results are corrected to the absolute lymphocyte
count. (a) C57-M4[s] on PBL from normal or C57-M4-bearing C57BL/6 mice, 14 days after
tumor inoculation. (b) 1310-D2-M3[s] on PBL from normal or B10-D2-M3-bearing C57BL/10
D2 mice, 21 days after tumor inoculation .
the responses to the T-cell mitogens, phytohemagglutinin and concanavalin. A,
and to alloantigens; i.e., stimulation to a peak response followed by inhibition at
higher antigen to mitogen concentrations (8, 14-16). This pattern was seen uni-
formly in the first 7-18 days after tumor inoculation. A less common pattern was
observed later in the course of tumor bearing. Thymidine incorporation was in-
hibited below elevated background levels at very low antigen concentrations, but
proliferation was stimulated at higher concentrations . This is illustrated in Fig.
1 b .
Interpretation of dose-response studies involving spleen and LN cell prolifera-
tion must account for two- to fivefold increases in total cell numbers in both cell
masses during the natural historyof bearing MCAtumors (9, 14-16) . Data from a
single experiment involving spleen cells are calculated both per unit cell number
and per cell mass, as illustrated in Fig. 2. All subsequent data involving both
spleen and LN cells are presented in terms of the respective total cell mass.
Spleen cells from normal animals proliferated slightly but detectably in some
instances when solubilized homologous tumor was added at higher dose levels. As
reported previously, spleen cells from tumor-bearing mice have high levels of
background [3H]TdR incorporation (8, 14). Two patterns of dose-response
kinetics were also observed when antigen was added to spleen cells of such
animals (Fig. 2 b and c) . The biphasic pattern involving low-dose inhibition was
more common late in the course of tumor bearing.
LN cells from tumor-bearinganimals also gave vigorous proliferative responses
to the solubilized homologous tumor preparation (Fig. 3) . LN cells from normal
mice did not proliferate significantly at any added concentration of solubilized
tumor antigen. The physical proximity of the LN cell mass to tumor-whether
regional, nonregional, or remote-was an important variable . The earliest
proliferative responses were in the nodes regional to the tumor; laternonregionalFIG.
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Dose-response relationship of spleen cells from normal and tumor-bearing mice FIG . 2 .
induced by soluble homologous tumor antigen. (a) Data expressed as cpm/106 spleen cells, 14
days after inoculation with C57-M4 tumor. (b) Same data shown in 2 a, expressed as
cpm/spleen. (c) Stimulation of spleen cells by C,57-M1[s] expressed in cpm/spleen 20 days
after inoculation with C,57-M1 tumor.
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Dose-response relationship of LN cells from normal and C57-M4-bearing C57BL/6
mice by the homologous antigen C57-M4[s]. (a) LN nonregional to tumor 28 days after tumor
inoculation. (b) LN regional to tumor 25 days after tumor inoculation.
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node masses were stimulated by homologous tumor antigen. As was found in the
case of spleen cells and PBL, a biphasic dose-response pattern also occurred in
LN cells taken from tumor-bearing animals, particularly in the nonregional node
masses. The inhibition pattern was infrequent in regional LN-cell masses.1156
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A highly significant positive correlation exists between the levelofbackground
[3H]TdR incorporation in tumor-bearing animals' spleen cells and the peak level
of incorporation stimulated by the homologous soluble tumor-antigen prepara-
tion, as illustrated in Fig. 4, and was true at each interval examined. The
correlation was clearer but less consistent for LN cells, and seemed not to apply
to PBL.
Changes in Patterns of In Vitro Proliferative Responses to Soluble Prepara-
tions of Homologous Tumor in Tumor-BearingAnimals as a Function ofInterval
After Tumor Inoculation. Proliferative responses to soluble tumor antigens
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￿
Relationship between the incorporation of the peak value of unstimulated ['H]TdR
incorporation (background) in spleen cells taken from C57-M4 tumor-bearing C57BL/6mice to
peak ['H]TdR incorporation in the same spleen cell cultures to which graded concentrations of
C57-M4[s] wasadded . The spleen cells were taken at intervals of 7 (O), 14 ("), 21 (0), or 2s+
(O) days after tumor inoculation. The line of regression (---) hasa value of r = 0.81, and slope
1.59.
were examined in PBL, regional and nonregional LN, and spleen cells taken at
varying times during the natural history of bearing 30 different MCA tumors in
six mouse strains. Data illustrative ofthe findings in most experiments are given
in Figs. 5 and 6.
Proliferative responses to the homologous antigen occurred earliest in LN
regional to the site oftumor inoculation, as early as 7 days in some experiments.
Levels ofresponse in the regional nodes were maximal at 14-22 days and declined
thereafter. The LN masses nonregional to the tumor site gave evidence of
stimulation later in the course of tumor bearing (14-25 days) and the decline,
which was regularly observed in regional nodes, did not occur.
Stimulation of proliferation in PBL by the homologous tumor antigen was
detected as early as 10 days, and remained detectable atleast 4-5 wk after tumor
inoculation. The level of proliferation assessed by [3H]TdR incorporationJAMEST. FORBES, YOSHINOBU NAKAO, AND RICHARD T. SMITH
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Dose-response relationship to homologous tumor antigen of PBL, LN, and spleen
cellsfrom C57-M4 tumor-bearing C57BL/6 mice 14, 21, and 28 days after tumorinoculation .
(a) PBL. (b) Spleen and LN cells.
increased to maximum values at 14-21 days and usually waned thereafter .
Proliferation of PBL in response to any antigenic preparation was frequently
reduced or undetectable late in the tumor-bearing period (30-40 days) . Prolifera-
tive responses of spleen cells to homologous antigen were detected after that in
regional node cells, but usually persisted throughout the course oftumor bearing,
and at a level increasing with time (Fig . 5) .
These data, together with those derived from experiments involving 30 other
tumors, permit limited statements on the natural evolution of soluble antigen-
evoked proliferative responses in the tumor-bearing mouse . The pattern is in
many respects similar to responses evoked to antigenic stimulation from other
sources; i .e ., earliest in regional LN, followed by more generalized distribution of
responsive cells to PBL, spleen, and distant LN (17) .
Proliferative Responses to Homologous Tumor Preparations of Spleen andIN
Cells Taken after Specific Tumor Immunization .
￿
The data described above1188
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Peak ['H]TdR incorporation levels taken from dose-response curves, in spleen cells
taken from normal or C57-M4 tumor-bearing C57BL/6 mice at 7, 14, 21, and 28 days after
tumor inoculation.
pertain only to the soluble antigen-stimulated proliferative behavior in vitro of
cells taken from tumor-bearing animals. Parallel studies were made of changes in
homologous antigen-induced proliferation of LN and spleen cells after both
tumor excision and soluble antigen immunization. The immunizing procedures
used were those which induced resistance to homologous tumor transplantation
(Table II). The results obtained were similar quantitatively to those in
tumor-bearing hosts; LN cells showed a high level of stimulated proliferation
with added homologous tumor preparations when assayed 14-30 days postexci-
sion (Tables III and V) . Spleen cell responses were also strong, although
proportionally less than LN cells, in terms of increment of incorporation over
background. No significant correlation was observed between background
incorporation levels and stimulated incorporation after either type of immuniza-
tion.
Evidence forImmunologic Specificity ofHomologous TumorAntigen-Induced
Lymphocyte Proliferation. A key issue in interpreting the significance of the
demonstrated in vitro proliferation of lymphoid cells after addition of solubilized
tumor is that of immunologic specificity . Does the soluble tumor preparation
stimulate proliferation in a general class of cells as a mitogen, or by triggering
proliferation in a lymphoid memory cell subset as a consequence of specific
receptor-antigenic ligand interaction? Evidence favoring the latter interpretation
was obtained through three experimental approaches, as well as in the data to be
described in a following section.
First, it was established that the tumors from which the antigen preparations
were solubilized were indeed immunogenic, although they varied widely in
capacity to elicit augmented resistance to challenge in the classictransplantation
test model (11) (Table II). Resistance to challenge was highly specific to the
homologous tumor in each instance (data not given), as has been firmly
established in this model (1-3).JAMES T. FORBES, YOSHINOBU NAKAO, AND RICHARD T. SMITH
TABLE II
Resistance of C57BL/6 Mice to Homologous Syngeneic Tumor Challenge
Induced by Tumor Bearing and Surgical Excision*
* Groups of C57BL/6 mice were injected s.c. in the hind limb with 1.0 x 105 cells from
the indicated syngeneic MCAtumors, andthe tumor-bearing limb excised surgically 7
days later . Groups of control mice were subject to limb excision at the same time. 7
days after excision log,, increments of the homologous tumor were injected s.c. on the
opposite side in groups of 5-7 animals; tumor growth and lethality were determined.
No detectable resistance was evoked toward anysyngeneic nonhomologous tumor and
these data are not shown .
$LDS, of tumor challenge calculated by method of Reed andMuench, given as log of the
number of cells resulting in 50% mortality.
TABLE III
Proliferative Responses to Various Syngeneic Solubilized TumorAntigens in
Regional IN Cells Taken30 Days AfterSurgical Excision of C57-M4 Tumor in
C57BL16 Mice*
Syngeneic tumor
antigen added
Peak [3H]TdR incorporation by cell source$
Controls
C57-M4[s]
tumor immunized
* Assays were performed on pools of regional and nonregional LN cells taken 30 days
after surgical amputation of the hind limb containing a C57-M4 tumor which had
been inoculated (1 x 105 cells s.c.) 7 days before excision. Control groups were con-
currently subjected to hind limb excision.
$Peak stimulation values (x 105) taken from dose-response titrations, calculated in
terms of the total LN mass examined.
1189
Secondly, experiments were performed in which tumors were amputated after
growth had been established, and an interval of 15-30 days had elapsed. This
eliminated tumor recurrence and permitted the general effects of tumor-bearing
per se to wane or disappear (8, 14). The effects of homologous solubilized tumor
LDS, of challenge tumor cells$
Tumordesignation
Control Tumorbearing andsurgical
(limb excision only) excision oftumor
C57-M2 3.2 >6.0
C,57-Ml <2.0 >6.0
C57-M4 <2.0 5.2
C57-M3 <2.0 4.6
C,57-M2 <2.0 3.6
mean cpm/LN cell mass t SE x 105
None 0 .04 t 0.005 3.8 t 0.02
C57-M2 0.06 f 0.002 6.0 f1 0 .60
C57-M3 0.06 t 0.002 4.4 t 0.30
C57-M4 0.08 t 0.007 12 .0 f 0.24
C,57-Ml 0.08 f 0 .004 4.6 f 0 .30
C,57-M2 0.04 f 0.003 3.6 t 0.281190
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preparations were assayed on LN and spleen cells taken from such animals.
These data, discussed in the previous section, suggest that memory cells capable
of responding to the tumor antigen at 30 days are present in highest concentra-
tion in the regional LN mass .
The third approach involved was to determine whether the solubilized tumor
preparations were actually immunogenic in syngeneic mice and whether immu-
nogenicity correlated with capacity to elicit in vitro proliferative reactions.
Resistance to tumor challenge was regularly elicited in animals immunized by
injecting solubilized tumor preparation in FCA over a 40 day period, then
challenging with incremental numbers of homologous living tumor cells (Tables
IV and V) . In vitro stimulation of LN and spleen cells with homologous tumor
antigens was regularly elicited in these circumstances.
TABLE IV
Resistance of C57BL/6 Mice to Homologous and Syngeneic Tumor Challenge Induced by
Immunization with Solubilized Tumor Preparations*
*Groups of C57BL/6 mice were injected i.m . with 0.1 mg of the indicated solubilized tumor
preparation, incorporated in FCA; 28 days later, the groups were reinjected s.c., with the identical
preparations. 7 days after this, the groups were injected i.m. with logo incremental numbers of
cells from the indicated tumor, andtumor growth and mortality recorded.
$ LDso calculated by the Reed-Muench method, given as the log of the number of cells eliciting 50%
mortality. The values of 3.0 x 105 or more represent significant resistance over control values.
§ Control mice received identical injections of FCA with RPMI-1640 media.
The results of each approach were consistent, therefore, with the interpretation
that the stimulatory capacity of the solubilized tumor preparations reflect
specific responses in receptor-bearing cell subsets. Moreover, in the experiments
used to illustrate the point, tumors of the series C57-M1 through C,57-M3, which
were most immunogenic in vivo, yielded antigenic preparations most stimulatory
to cells from tumor-bearing or tumor-immune animals in vitro (C57-M2 and
C57-M4). Those least evocative of in vivo resistant were least stimulatory
(C,57-M2 and C57-M3) in vitro. Removal of the tumor by amputation gave
augmented rather than reduced responses in vitro, as compared with those of
tumor-bearing animals. This would appear to exclude a mitogenic effect on a
susceptible proliferating cell subpopulation peculiar to the tumor-bearing state.
The data appear to justify the use of the term "tumor antigen" in relation to the
solubilized tumor material .
Immune Responses to Multiple Syngeneic Tumor Antigens in the Tumor-
Tumor used to
challenge after
immunizing
LDso of challenge tumor cells, in groups
indicated tumor antigen preparation$
immunized with
procedure Control§ C57-M2[s] C,57-M2[s] C57-M3[s] C,57-M1[s] C57-M4[s]
C57-M2 <3.0 4.5 3.6 3.5 3.0 <3.0
C57-M3 <3 .0 <3.0 <3.0 3.6 <3.0 <3.0
C57-M4 <3.0 <3.0 <3.0 <3.0 <3.0 3.4
C57-M1 <3 .0 <3.0 <3.0 <3.0 3.6 4.0JAMES T. FORBES, YOSHINOBU NAKAO, AND RICHARD T. SMITH
TABLE V
Effect of Immunizing with Homologous or Syngeneic Solubilized TumorAntigens in CFA
on Proliferation Induced In Vitro by Solubilized Antigens, 45 days later*
1191
* Groups of mice were injected i.m . with 0.1 mg of the indicated soluble tumor antigen in RPMI-1640,
or medium alone in the case of controls in FCA. The injection was repeated 30 days later s.c., and
spleen or LN cells assayed 15 days later for proliferative responses to solubilized syngeneic tumor
antigens .
Bearing Mouse. It was apparent early in these studies that lymphoid cell
proliferation was regularly elicited by preparations derived from syngeneic MCA
tumors in addition to that induced by those from the homologous tumor. These
so-called cross-reactions to solubilized tumor antigens have been studied in four
different experimental contexts: First, responsesof LN or spleen cells taken after
tumor excision were examined in parallel with the in vivo challenge in which
tumor-unique transplantation resistance was demonstrated. Proliferative re-
sponses of LN cells to various syngeneic tumor antigens are illustrated by that
shown in Table 111. The strongest responses in terms of [3H]TdR incorporation
were uniformly found with the homologous tumor preparation. Proliferation was
also elicited by syngeneic tumor antigen preparations ; this responsiveness to
syngeneic tumor antigens was not paralleled by resistance to tumor transplanta-
tion.
Second, transplantation resistance and proliferative responses to multiple
syngeneic antigens were assessed after active immunization with solubilized
tumor antigen; spleen and LN cells were examined from animals, whichhad been
immunized with solubilized antigens in FCA. Parallel in vivo challenges were
made with living tumor cells. The results, as exemplified in Tables IV and V,
were unexpected in that not only were proliferative responses elicited in LN and
spleen cells against syngeneic tumor antigens, but in vivo cross-resistance was
induced toward some syngeneic tumors. For example, C57-M2 was resisted by
animals immunized with several preparations while others, C57-M3 and
C57-M4, were resisted only by animals which were immunized with the
respective homologous antigen preparation. This represents the first known
evidence that transplantation immunity evoked by chemically induced fibrosar-
comas in mice may be induced by shared or cross-reacting antigens.
Tumor antigen used to
immunize source of
spleen or LN cells
Mean peak ['H]TdRincorporation values/cell
solubilized tumor antigen added in
None C57-M2[s] C57-M3[s]
mass (x 106) by
assay
C57-M4[s]
No tumor, FCA, andmedium alone
Spleen 0.40 0.38 0.61 0.91
LNC 0.05 0.04 0.04 0.11
C57-M2[s] in FCA
Spleen 2.62 9.14 10.28 29.26
LNC 0.47 1.70 2.77 4.22
C47-M4[s] in FCA
Spleen 1.94 4.94 7.50 25.97
LNC 0.30 1.36 1 .07 2.641192
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Third, checkerboard assays of proliferative responses to multiple syngeneic
antigen preparations by various lymphoid cell masses were made at a single time
(20-33 days) after tumor inoculation from individual mice bearing one of several
syngeneic tumors; peak incorporation values taken from dose-response titrations
and calculated in terms of total cell mass are presented for exemplary
experiments involving tumors in four sublines of C57BL/10 mice (Table VI). The
data illustrate that extensive proliferative responses were elicited toward
syngeneic tumor-antigen preparations. In this single-time, cross-section type of
experiment, the responses to homologous tumors were not always the strongest
ones. Some tumors appeared to evoke immune responses to more syngeneic
tumor-antigen preparations than others. The data, therefore, do not support the
occurrence of a shared tumor antigen, represented more or less equally in each
member of a family of syngeneic tumors.
Fourth, checkerboard studies were made of different cell masses at varying
intervals after tumor inoculation. The data, as exemplified by the experiments
shown in Fig. 7, show that the so-called cross-reacting proliferative responses
elicited by syngeneic tumor antigens are both time-course and cell-mass
dependent. The most frequent pattern observed was that significant or strong
proliferative responses to homologous tumor antigens appeared first in the
regional LN and PBL at 10-14 days and later at 2-3 wk in spleen or nonregional
LN masses. Proliferation in response to syngeneic tumor antigens appeared at
2-3 wk in the regional LN masses and reached maximal levels in spleen and
nonregional LN masses at 3-4 wk. Homologous tumor-antigen responsiveness
frequently was attenuated or absent in the regional LN at 3-4 wk at the same
time responses to syngeneic tumors were significant at the same cell mass. The
results of 14 similar experiments evaluating changes in temporal occurrence and
cell-mass distribution of responses to syngeneic tumor antigens are summarized
in Table VII.
Discussion
Solubilization of the tumor cells of MCA-induced fibrosarcomas gave prepara-
tions which induce tumor resistance in vivo and stimulate lymphoid cells taken
from tumor-bearing or tumor-immune mice to proliferate in vitro. The assay
developed to measure proliferative responses in vitro appears to reflect interac-
tions between tumor antigens and immunocompetent cells. The evolution of cell
proliferative responses in various lymphoid cell masses during the natural history
of tumor bearing apparently involved accumulation of antigen responsive cells
first in the regional LN ; this is followed by spread to more remote lymphoid cell
masses. These proliferative responses were initially strongest toward the homolo-
gous tumor-antigen complex, but strong responses to some but not all syngeneic
tumor antigens were detected after 2-4 wk of tumor bearing. The time-course and
cell-mass patterns of such "cross-reactions" are interpreted to indicate the
existence of multiple antigenic components of the tumors, some of which are
shared, others apparently not.
The assay procedure developed and used in these studies proved reliable and
reproducible, although its several important limitations require stipulation.JAMES T. FORBES, YOSHINOBU NAKAO, AND RICHARD T. SMITH
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TABLE VI
Effect of Bearing Various Syngeneic Tumors for a 3 wk period Upon Solubilized Tumor
Antigen-Induced Proliferation in Spleen Cells of Congenic Resistant C57BLI10 Mouse
Sublines*
Mean peak [6H]TdR incorporation per spleen (x 106), by
origin of solubilized tumor antigen
Subline and
￿
No. of
subline tumor
￿
spleen cells
￿
No
* Tumor cells taken from third passage tumor induced by MCA in each C57BL/10 subline indicated
were inoculated (1 x 106 cells s.c.) 20-23 days earlier, andquadriplicate cultures of spleen cells were
incubated 3 days after adding various amounts (0.01-50 Al) of the indicated solubilized tumor
antigen prepared from the homologous and other syngeneic tumors. Proliferation was assayed in
terms of [6H]TdR incorporation; peak mean values for incorporation taken from dose-response
curves, were calculated as counts per minute per spleen.
inoculated (x 106) antigen
added
B10-Ml
Tumor antigen
1310-M2 B10-M3 1310-M4
C57BL/10
B10 (no tumor) 75 0.24 0.39 0.61 0.68 0.57
B10-Ml (tumor) 151 1.43 1.48 2.02 2.58 2.42
B10-M5 169 1.50 2.40 2.00 3.81 3.21
1310-M2 170 3.06 3 .69 2.47 4.72 3.61
1310-M4 181 1.50 2.24 1.91 3.99 3.36
1310-M3 270 5.96 8.06 6.99 14.41 11 .86
BR. C2-M1 BR . C2-M2 BR. C2-M3
C57BL/10 - Br
B10- BR (no tumor) 100 0.20 1.80 0.90 0.60
1310-13R .C2-M3 242 1.40 7.10 6.80 4.90
1310-1311-C2-Ml 258 2.30 5.30 4.60 3.40
B10-BR-C2-M2 452 3.10 16.40 11 .80 10.90
A-C2-M1 A-C3-M1 A-C3-M2 A-C3-M3
C57BL/10 - A
1310- A (no tumor) 98 0.21 0.24 0.45 0.37 0.21
1310- A. C2-M2 146 0.75 1.60 3.30 0.94 1.40
1310 - A- C3-M3 155 0.70 0.70 1.10 0.57 0.63
B10- A- C3-M2 220 1.40 2.60 3.90 1.80 2.20
B10-A.C3-Ml 268 3.50 5.80 10.60 3.90 3.50
1310-A -C2-Ml 278 2.70 6.90 10.60 3.30 4.80
D2-M1 D2-M2 M2-M3
C5713L/10- D2
B10-D2 (no tumor) 91 0.29 0.89 1 .20 0.47
1310-D2-Ml 133 0.91 2.50 2.70 2.00
B10-D2-M2 178 1.50 7.00 6.60 4.50
1310-D2-M3 261 2.80 17.20 10.70 6.301194
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FIG. 7. Dose-response relationship between homologous (B10 .C2-M3[s]) and syngenic
(1310-C2-M1[s] and B10 .C2-M2[s]), antigens of spleen and regional LN cells (R.LNC) from
normal and B10-C2M3 tumor-bearing C57BL/10, 22 days after tumor inoculation . (a)
Regional LN . (b) Spleen .
First, the stimulatory components of the solubilized tumorpreparations have not
been isolated and identified in such a way as to provide a quantitative basis for
relating the antigen content of different preparations from the same tumor .
Accordingly, it has been necessary to perform, in each test, dose-response
titrations involving varying concentrations of each preparation over a 1,000-fold
range . While this approach imposes logistical restraints upon the number of
variables which can be explored in a single experiment, no alternative measure of
antigen content seems completely appropriate at this time . Secondly, the
activity in these preparations did not always survive freezing or lyophilization in
terms of a reproducible capacity to stimulate equal levels of proliferation .
However, the activity remained constant at 4°C for 3-4wk . This required regular
production of fresh preparations, and these varied somewhat in activity from
batch to batch. Both of these limitations can probably be eliminated through use
of semipurified preparations now under investigation (R . Blackstock, Schimpff,
and Smith, unpublished data) .TABLE VII
Summary of Observed Patterns of Lymphoid Cell Stimulated by Solubilized Tumor
Antigens, at Varying Intervals During Tumor Growth
Intervals after
inoculation
of tumor
days
1-10
11-22
22-38
JAMES T. FORBES, YOSHINOBU NAKAO, AND RICHARD T. SMITH
15-30
postsurgical
excision of
tumor
Occurrence of maximal stimulation and specificity in terms of homologous
syngeneic and syngeneic antigens, by cell mass
PBL
Detectable,
homologous
tumor antigen
Strong,
homologous,
and syngeneic
Weak or
undetectable
particularly in
terminal stages
Regional
lymph nodes
Strong,
homologous,
tumor only
Strong,
homologous,
and syngeneic
Weak or
undetectable to
homologous
antigen;
syngeneic
antigens give
variable
stimulation
Strongest;
homologous
usually
greatest, also
detectable
syngeneic
Nonregional
lymph nodes
No stimulation
Strong,
homologous,
and syngeneic
Strong,
homologous
and syngeneic,
waning
terminally
Moderate;
homologous
and syngeneic
Spleen
No stimulation
Strong,
homologous,
and syngeneic
Strong
homologous,
and
syngeneic
Moderate ;
homologous
and syngeneic
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The dose-response assays revealed an as yet unexplained inhibition of
proliferation at low antigen concentrations. This inhibitory activity reduced the
high spontaneous "background incorporation" levels of [3H]TdR, which are
regularly encountered in spleen or LN cell masses taken from tumor-bearing
animals, to lower levels approaching those characteristic of normal spleen or LN
cells. This inhibitory effect occurred with syngeneic tumorpreparations as well as
homologous ones, and the pattern of time and cell mass involved was similar to
that of the stimulatory response . The biphasic characterof the inhibition-stimu-
lation phenomenon could indicate either that the solubilized tumor preparation
contains both inhibitory and stimulatory components affecting the same cells; or
that the cell mixtures assayed include both proliferating cell subsets, which are
subject to inhibition, and other subsets which are subject to stimulation. The
data do not yet permit any firm conclusion with respect to the nature of
significance of the inhibitory phenomenon in this model.
Baldwin et al . (18-20) have also described specific inhibition of in vitro lymphocyte-
mediated tumor cytotoxicity by addition of solubilized tumor antigen. The low-dose
inhibition observed appears, however, distinctive from that reported by Baldwin et al. and
the inhibition which occurs in this system when amounts of antigen areaddedabove those1196
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which induce optimal stimulation proliferation in this system, or which occurs when
serum from a tumor-bearing animal is added, the so-called blocking effect (Forbes, Calder-
wood, and Smith, unpublished data, and others [references 21-23]).
The most likely explanation of the significant positive correlation between the
background level of [3H]TdR incorporation by spleen cells from tumor-bearing animals
and antigen-stimulated incorporation is that the same cell subsets are responding in vivo
to antigen-driven proliferation and in vitro to added antigen (24-32) . The larger the subset
size, the higher the level of in vivo and in vitro proliferation. On the other hand, it is possi-
ble that the in vivo proliferation indicated by high level spontaneous proliferation may pro-
vide triggering or augmenting influence which permits effective responses to the added
antigens in vitro . An analogous effect has been described recently in experiments showing
a synergistic or triggering action of alloantigen responsive cells upon susceptibility to
B-cell mitogens (33) .
The assay data reflect proliferative activity which correlates with the in vivo
immunogenicity of the tumor or its soluble derivative. It has not been correlated with data
obtained by assay techniques which depend upon cell-mediated cytotoxicity (6, 7), colony
inhibition (4, 5), or lymphokine production (34-36) as end points. It appears to
complement data obtained by these techniques in several ways. Because DNA synthesis
measured in the assay is related to the number of proliferating cells, it has the potential of
permitting estimation of the original subset size of a responding lymphoid cell subpopula-
tion. Moreover, the possibility exists of examining such subsets for individual specificity
toward components of the tumor-antigen complex through techniques for eliminating one
proliferating subset and testing for residual responding cells, as has been done in other
contexts (37-40) .
Lymphoid cell proliferation occurred in response to antigens derived from some but not
all syngeneic tumors, whether taken from a tumor-bearing or tumor-immune animal. This
differs somewhat from the reported results in other in vitro assay systems. Most in vitro
studies have revealed nearly universal cross-reactivity between chemically induced (41-44)
or spontaneous (43) tumors to the same histogenetic type (41), and those induced by the
same oncogenic viruses (44) . The patterns of cross-reactions observed in the MCA-induced
tumors examined here are most consistent with immunologic responses to multiple shared
or unshared specificities on each tumor rather than responses toward a single, broadly
shared tumor-associated antigen . The responses to the soluble antigen preparations as
immunogens, the time-course of lymphoid cell responses, and the pattern of spread
throughout the various cell masses, each suggest multiple independent subset responses to
tumor-born antigenic structures.
These antigens may reflect quantitative differences in cell surface expression of a large
number of normal structures, as well as qualitative differences related to oncogenic
events. Such structures could include any or all of the following: virus related membrane
components (44-46), cell differentiation associated or embryonic structures (41-49),
membrane structures detected as histocompatibility antigens (44, 50-53), or unique
structures formed by concatenations of any of these as a tumor-specific matrix as
suggested by Boyse and Old (54, 55). That each specificity is related to tumor-specific
transplantation rejection is not necessarily required by such a hypothesis. For example,
homologous tumor cells would be subject to in vivo immunologic attack by cytotoxic cells
or antibody elicited by each antigenic structure of the array of specificities on that tumor.
A syngeneic tumor, on the other hand, would be exposed in vivo only to those potentially
destructive elements of the immune response directed toward shared structures. Such
quantitative differences could conceivably account for tumor-unique rejection of homolo-
gous tumors while syngeneic tumor implants survive, since in the transplantation model a
growth or no growth end point is assessed .JAMES T. FORBES, YOSHINOBU NAKAO, AND RICHARD T. SMITH
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An important and possibly practical implication of the data presented is that in
order to assess tumor-specific immunity in tumor-bearing man or animals,
consideration must be given to multiple variables. These include the interval
after tumor inoculation or development, the lymphoid cell mass examined, and
the extent of multiple specificities defined. Single time-frame or cell-mass
sampling, such as examinationof PBL only, does notnecessarilyreflect the broad
immunologic committment of the individual to tumor-borne antigenic specifici-
ties or the cellular ecology of this committment. These variables have been
largely unaccounted for in most previous work aimed at defining tumor-specific
immunity. The total "cell ecology" approach appears essential to interpreting
current studies aimed at accounting tumor responsive lymphoid cells in terms
of responding cell class or subclass.
Summary
Experiments were designed to explore the apparent paradox that methylcholan-
threne-induced tumors of mice evoke tumor-unique transplantation immunity
but reveal almost complete cross-reacting antigenicity in tests of lymphocyte
behavior in vitro. The approach involved use of tumor membranes solubilized in
3 M KCI, employed both as the stimulating antigen source in a new in vitro
proliferation assay of lymphocyte recognition, and as immunogens in vivo. The
kinetics of the assay resembled those of in vitro tests of mitogen or specific
antigen stimulation in other systems. Lymphoid cell proliferation was assessed in
peripheral blood leukocytes, lymph nodes (LN), and spleen over the course of
tumor bearing, and in animals immunized by tumor amputation or with the
solubilized antigens . The pattern of spread of reactivity was from regional LN to
spleen, peripheral blood, and nonregional nodes in each circumstance . An
unexplained low antigen dose inhibitory phenomenon was encountered in
spontaneously proliferating cell subpopulations taken from some tumor-bearing
animals. In vitro responses to some but not all solubilized antigens made from
multiple syngeneic tumors were detected in each circumstance. The soluble
antigens also induced shared resistance to some tumors. The patterns of spread of
responsiveness to syngeneic tumor antigens, the time-course, and relative
intensity were most compatible with independent clonal responses to multiple
tumor-borne antigens, some but not all of which are shared in any family of
syngeneic tumors.
Received for publication 20 December 1974.
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